LYEL · Lyell Immunopharma, Inc.

$14.32 -0.21 (-1.45%) At close · Aug 31

Russell 2000 member Rebalance outlook locked

Market Cap

$356.06M

24.51M

Notices of intent to sell restricted or control shares, filed with the SEC on Form 144 by insiders and affiliates. A Form 144 signals a planned sale — it does not confirm the shares were actually sold.

Filed	Seller	Relationship	Shares	Market Value	Approx. Sale	Broker
2023-08-15	Klausner Richard	Director	4,485	$10,271	2023-08-15	Raymond James & Associates, Inc.
2023-08-15	Klausner Richard	Director	4,485	$10,271	2023-08-15	Raymond James & Associates, Inc.
2023-08-15	Klausner Richard	Director	44,565	$102,054	2023-08-15	Raymond James & Associates, Inc.
2023-08-15	Klausner Richard	Director	4,485	$10,271	2023-08-15	Raymond James & Associates, Inc.
2023-07-17	Klausner Richard	Officer, Director	3,300	$9,570	2023-07-13	Raymond James & Associates, Inc.
2023-07-17	Klausner Richard	Officer, Director	3,300	$9,570	2023-07-13	Raymond James & Associates, Inc.
2023-07-17	Klausner Richard	Officer, Director	3,300	$9,570	2023-07-13	Raymond James & Associates, Inc.
2023-07-17	Klausner Richard	Officer, Director	14,500	$42,050	2023-07-13	Raymond James & Associates, Inc.

Showing 1–8 of 8 filings

Key facts CIK 1806952 CUSIP 55083R203 13F (30d) 90 filings 85 filers Visit website Investor relations